SCHEMBL6064530

SCHEMBL6064530

O=C(O)c1ccc(S(=O)(=O)O)c(S(=O)(=O)O)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.56
HSD17B10 Q99714 6/20 0.49
ALDH1A1 P00352 6/20 0.49
TDP1 Q9NUW8 2/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
SELL P14151 1/20 0.47
SELP P16109 1/20 0.47
KDM4E B2RXH2 3/20 0.42
HPGD P15428 2/20 0.42
TSHR P16473 3/20 0.40
CYP2C9 P11712 2/20 0.40
LDHA P00338 1/20 0.40
HIF1A Q16665 1/20 0.40
CYP1A2 P05177 1/20 0.39
ALOX15 P16050 1/20 0.39
ALB P02768 1/20 0.38
MMP2 P08253 1/20 0.38
MAPT P10636 1/20 0.38
MPL P40238 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrazine SCHEMBL9314972 0.96 CYP2D6 (0.53) CYP2D6HSD17B10ALDH1A1TDP1CASP1
SCHEMBL6292102 0.86 SELL (0.54) CYP2D6HSD17B10ALDH1A1TDP1CASP1
SCHEMBL27262586 0.84 SELL (0.57) CYP2D6HSD17B10ALDH1A1TDP1CASP1
SCHEMBL27485805 0.84 SELL (0.52) CYP2D6HSD17B10ALDH1A1TDP1CASP1
SCHEMBL27653670 0.84 SELL (0.52) CYP2D6HSD17B10ALDH1A1TDP1CASP1
Water SCHEMBL27471406 0.82 SELL (0.50) CYP2D6HSD17B10ALDH1A1TDP1CASP1
SCHEMBL27653713 0.82 SELL (0.55) CYP2D6HSD17B10ALDH1A1TDP1CASP1
SCHEMBL27877119 0.81 CYP2D6 (0.49) CYP2D6HSD17B10ALDH1A1TDP1CASP1
SCHEMBL27827651 0.81 CYP2D6 (0.49) CYP2D6HSD17B10ALDH1A1TDP1CASP1
SCHEMBL28018875 0.81 CYP2D6 (0.49) CYP2D6HSD17B10ALDH1A1TDP1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102523-A1 PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF JUBILANT DRAXIMAGE INC (CA) 2026-04-16 US claimed
US-12440583-B2 Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof JUBILANT DRAXIMAGE, INC. (CA) 2025-10-14 US claimed
EP-3592735-B1 AN IMPROVED PROCESS FOR THE PREPARATION OF TETROFOSMIN OR ACID ADDITION SALT THEREOF JUBILANT GENERICS LTD FORMERLY A DIVISION OF JUBILANT LIFE SCIENCES LTD (IN) 2024-03-20 EP claimed
US-20240050598-A1 PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF JUBILANT DRAXIMAGE INC. (CA) 2024-02-15 US claimed
US-11857647-B2 Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof JUBILANT DRAXIMAGE, INC. 2024-01-02 US claimed
EP-1085984-B1 I INKJET RECEPTOR MEDIA AND COATING SOLUTIONS THEREFOR MINNESOTA MINING & MFG (US) 2005-12-28 EP claimed
US-6383612-B1 PIGMENT METAL SALT COATING IMPREGNATED INTO POROUS MEMBRANE; AROMATIC OR ALIPHATIC DRYING AGENT WITH SULFONIC, CARBOXYLIC, PHENOLIC, AND/OR HYDROXYL FUNCTIONAL GROUPS; WATERPROOFING, COLORFASTNESS, NONSMEARING 3M INNOVATIVE PROPERTIES COMPANY 2002-05-07 US claimed
EP-1085984-A1 INK-DRYING AGENTS FOR INKJET RECEPTOR MEDIA MINNESOTA MINING AND MANUFACTURING COMPANY (US) 2001-03-28 EP claimed
WO-1999065702-A1 INK-DRYING AGENTS FOR INKJET RECEPTOR MEDIA MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-12-23 WO claimed
US-20260102523-A1 PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF JUBILANT DRAXIMAGE INC (CA) 2026-04-16 US disclosed
US-12440583-B2 Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof JUBILANT DRAXIMAGE, INC. (CA) 2025-10-14 US disclosed
US-20250299889-A1 SOLID ELECTROLYTIC CAPACITOR ELEMENT AND SOLID ELECTROLYTIC CAPACITOR PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) 2025-09-25 US disclosed
US-20250104928-A1 ELECTROLYTIC CAPACITOR AND METHOD OF MANUFACTURING SAME PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) 2025-03-27 US disclosed
US-12131872-B2 Electrolytic capacitor and method for producing same PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) 2024-10-29 US disclosed
US-20040213928-A1 oriented film having at least one microfibrillated surface comprising polymeric microflakes; can receive jettable materials; good ink receptive properties particularly for solvent based inks 3M INNOVATIVE PROPERTIES COMPANY 2004-10-28 US disclosed
US-6753080-B1 Receptor medium having a microfibrillated surface 3M INNOVATIVE PROPERTIES COMPANY 2004-06-22 US disclosed
WO-2003064166-A1 RECEPTOR MEDIUM HAVING A MICROFIBRILLATED SURFACE 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-08-07 WO disclosed
US-6383612-B1 PIGMENT METAL SALT COATING IMPREGNATED INTO POROUS MEMBRANE; AROMATIC OR ALIPHATIC DRYING AGENT WITH SULFONIC, CARBOXYLIC, PHENOLIC, AND/OR HYDROXYL FUNCTIONAL GROUPS; WATERPROOFING, COLORFASTNESS, NONSMEARING 3M INNOVATIVE PROPERTIES COMPANY 2002-05-07 US disclosed
EP-1085984-A1 INK-DRYING AGENTS FOR INKJET RECEPTOR MEDIA MINNESOTA MINING AND MANUFACTURING COMPANY (US) 2001-03-28 EP disclosed
WO-1999065702-A1 INK-DRYING AGENTS FOR INKJET RECEPTOR MEDIA MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11857647-B2 Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof TREH, TYMP, PRCP CYP2D6 2986/4885HSD17B10 4728/4885ALDH1A1 4783/4885
US-20260102523-A1 PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TREH, CD68, THPO CYP2D6 1339/4885HSD17B10 4328/4885ALDH1A1 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.